Influence of CYP3A and CYP2C19 genetic polymorphisms on the pharmacokinetics of cilostazol in healthy subjects. (Q45974065)

18 December 2017

title

Influence of CYP3A and CYP2C19 genetic polymorphisms on the pharmacokinetics of cilostazol in healthy subjects. (English)

1 reference

18 December 2017

1 reference

H-D Yoo

1

1 reference

18 December 2017

S-A Park

series ordinal

2

1 reference

18 December 2017

H-Y Cho

series ordinal

3

1 reference

18 December 2017

Y-B Lee

series ordinal

4

1 reference

18 December 2017

language of work or name

English

0 references

publication date

10 June 2009

1 reference

18 December 2017

Clinical Pharmacology & Therapeutics

published in

1 reference

18 December 2017

volume

86

1 reference

18 December 2017

issue

3

1 reference

18 December 2017

page(s)

281-284

1 reference

18 December 2017

Pharmacokinetics of multiple-dose oral cilostazol in middle-age and elderly men and women

cites work

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2009.90

Characterization of human cytochrome p450 enzymes involved in the metabolism of cilostazol.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2009.90

CYP3A activity in African American and European American men: population differences and functional effect of the CYP3A4*1B5'-promoter region polymorphism

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2009.90

Association of the CYP3A4*1B 5'-flanking region polymorphism with cyclosporine pharmacokinetics in healthy subjects

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2009.90

Population pharmacokinetics of cyclosporine in kidney and heart transplant recipients and the influence of ethnicity and genetic polymorphisms in the MDR-1, CYP3A4, and CYP3A5 genes.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2009.90

Sequence diversity in CYP3A promoters and characterization of the genetic basis of polymorphic CYP3A5 expression

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2009.90

Association of the CYP3A5 A6986G (CYP3A5*3) polymorphism with saquinavir pharmacokinetics

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2009.90

Lipid-lowering response to statins is affected by CYP3A5 polymorphism

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2009.90

Tacrolimus pharmacogenetics: the CYP3A5*1 allele predicts low dose-normalized tacrolimus blood concentrations in whites and South Asians

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2009.90

Variation in oral clearance of saquinavir is predicted by CYP3A5*1 genotype but not by enterocyte content of cytochrome P450 3A5.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2009.90

The activation of the biguanide antimalarial proguanil co-segregates with the mephenytoin oxidation polymorphism--a panel study

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2009.90

The effect of CYP2C19 polymorphism on the pharmacokinetics and pharmacodynamics of clopidogrel: a possible mechanism for clopidogrel resistance

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2009.90

CYP2C19 genotype is a major factor contributing to the highly variable pharmacokinetics of voriconazole

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2009.90

Genetic polymorphisms in MDR1 and CYP3A4 genes in Asians and the influence of MDR1 haplotypes on cyclosporin disposition in heart transplant recipients

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2009.90

Molecular basis of ethnic differences in drug disposition and response

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2009.90

The role of common variants of ABCB1, CYP3A4, and CYP3A5 genes in lipid-lowering efficacy and safety of simvastatin treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2009.90

Cilostazol has beneficial effects in treatment of intermittent claudication: results from a multicenter, randomized, prospective, double-blind trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2009.90

7 January 2021

Cilostazol pharmacokinetics after single and multiple oral doses in healthy males and patients with intermittent claudication resulting from peripheral arterial disease

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2009.90

7 January 2021

In vitro metabolism and interaction of cilostazol with human hepatic cytochrome P450 isoforms

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2009.90

7 January 2021

Clinical impact of CYP2C19 polymorphism on the action of proton pump inhibitors: a review of a special problem.

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2009.90

7 January 2021

Genetic differences in CYP2C19 single nucleotide polymorphisms among four Asian populations

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2009.90

7 January 2021

Effects of CYP3A inhibition on the metabolism of cilostazol

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2009.90

7 January 2021

Identifiers

DOI

10.1038/CLPT.2009.90

1 reference

18 December 2017

Dimensions Publication ID

1022858277

0 references

1 reference

18 December 2017